River Road Asset Management LLC Trims Stock Position in Haemonetics Corporation $HAE

River Road Asset Management LLC trimmed its position in Haemonetics Corporation (NYSE:HAE) by 33.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,102,140 shares of the medical instruments supplier’s stock after selling 552,650 shares during the quarter. River Road Asset Management LLC’s holdings in Haemonetics were worth $88,337,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares during the last quarter. Caxton Associates LLP acquired a new position in Haemonetics in the first quarter valued at approximately $216,000. United Services Automobile Association acquired a new position in Haemonetics in the first quarter valued at approximately $212,000. Empowered Funds LLC grew its position in Haemonetics by 9.1% in the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on HAE. Barrington Research reduced their target price on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Citigroup increased their price target on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, May 28th. JPMorgan Chase & Co. cut their price objective on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, May 21st. Finally, Mizuho upped their target price on shares of Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $78.33.

Haemonetics Stock Up 1.9%

Shares of NYSE:HAE opened at $74.10 on Friday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The firm has a market capitalization of $3.37 billion, a PE ratio of 36.68, a price-to-earnings-growth ratio of 1.46 and a beta of 0.56. The firm’s 50-day moving average is $63.61 and its two-hundred day moving average is $67.10. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. During the same quarter in the prior year, the company earned $1.24 earnings per share. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts predict that Haemonetics Corporation will post 5.22 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.